[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Barchart Premier: The most comprehensive method for keeping track of all your investments. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Moonlake Immunotherapeutics (MLTX)

Moonlake Immunotherapeutics (MLTX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Market News and Commentary

MoonLake's Third Consecutive Quarter Without Revenue Before the BLA Decision

MoonLake Immunotherapeutics (MLTX) reports first-quarter 2026 earnings before the market opens on Monday, May 11, with analysts forecasting a loss of $0.91 per share. The biotech's stock has struggled over the past year, and investors will scrutinize whether the company's lead drug candidate, sonelokimab, can deliver clinical progress that justifies its valuation. With regulatory milestones on the horizon and a sharply divided analyst community, this report could set the tone for the remainder of 2026.

MoonLake Immunotherapeutics is a clinical-stage biopharmaceutical company developing sonelokimab, a novel Nanobody therapy targeting inflammatory diseases including hidradenitis suppurativa, psoriatic arthritis, axial spondyloarthritis, and psoriasis. The company has no...

Fundamentals

See More
  • Market Capitalization, $K 1,223,680
  • Shares Outstanding, K 71,728
  • Annual Sales, $ 0 K
  • Annual Income, $ -227,320 K
  • EBIT $ -245 M
  • EBITDA $ -242 M
  • 60-Month Beta 1.01
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 4.03

Options Overview Details

View History
  • Implied Volatility 68.66% (-8.88%)
  • Historical Volatility 74.81%
  • IV Percentile 21%
  • IV Rank 12.52%
  • IV High 238.49% on 09/17/25
  • IV Low 44.37% on 06/30/25
  • Expected Move (DTE 4) 1.45 (7.67%)
  • Put/Call Vol Ratio 0.04
  • Today's Volume 6,864
  • Volume Avg (30-Day) 858
  • Put/Call OI Ratio 0.20
  • Today's Open Interest 42,598
  • Open Int (30-Day) 42,436
  • Expected Range 17.40 to 20.29

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 19 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/26
See More
  • Average Estimate $-0.91
  • Number of Estimates 4
  • High Estimate $-0.86
  • Low Estimate $-0.97
  • Prior Year $-0.63
  • Growth Rate Est. (year over year) -44.44%

Price Performance

See More
Period Period Low Period High Performance
1-Month
16.01 +17.68%
on 04/29/26
21.00 -10.29%
on 05/11/26
+0.88 (+4.90%)
since 04/10/26
3-Month
15.27 +23.38%
on 02/12/26
21.00 -10.29%
on 05/11/26
+3.05 (+19.32%)
since 02/11/26
52-Week
5.95 +216.64%
on 09/29/25
62.75 -69.98%
on 09/26/25
-19.63 (-51.03%)
since 05/09/25

Most Recent Stories

More News
MoonLake's Third Consecutive Quarter Without Revenue Before the BLA Decision

Barchart Research What to Expect from MLTX Earnings MLTX Generated May 8, 2026 Current Price $17.06 EPS Estimate $$-0.91 Consensus Rating Moderate Buy Average Move 3.00% MoonLake's Third Consecutive Quarter...

MLTX : 18.84 (+10.43%)
MoonLake's Third Consecutive Quarter Without Revenue Before the BLA Decision

Barchart Research What to Expect from MLTX Earnings MLTX Generated May 8, 2026 Current Price $17.06 EPS Estimate $$-0.91 Consensus Rating Moderate Buy Average Move 3.00% MoonLake's Third Consecutive Quarter...

MLTX : 18.84 (+10.43%)
MoonLake's Third Consecutive Quarter Without Revenue Before the BLA Decision

Barchart Research What to Expect from MLTX Earnings MLTX Generated May 8, 2026 Current Price $17.06 EPS Estimate $$-0.91 Consensus Rating Moderate Buy Average Move 3.00% MoonLake's Third Consecutive Quarter...

MLTX : 18.84 (+10.43%)
ImageneBio Appoints Immunology Drug Development Veteran Dr. Ben Porter-Brown as Chief Medical Officer

Brings 20+ years of clinical development experience in autoimmune and inflammatory diseases, including OX40/OX40L program leadership Will build and lead Imagene’s clinical organization and drive...

MLTX : 18.84 (+10.43%)
IMA : 5.61 (+6.05%)
BioTech Breakout: MoonLake Up 30% On FDA Wins

MoonLake shares are rallying after the FDA granted Fast Track designation for its lead drug and cleared the path for a major filing later this year.

MLTX : 18.84 (+10.43%)
Stocks Boosted by Chip Demand Optimism

The S&P 500 Index ($SPX ) (SPY ) on Thursday closed up +0.26%, the Dow Jones Industrials Index ($DOWI ) (DIA ) closed up +0.60%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) closed up +0.32%. March E-mini...

MSTR : 195.94 (+4.45%)
BLK : 1,081.32 (-0.32%)
AMAT : 443.62 (+1.88%)
MPC : 252.48 (+3.11%)
SNDK : 1,547.56 (-0.95%)
ADI : 422.73 (+1.49%)
MLTX : 18.84 (+10.43%)
$IUXX : 29,320.66 (+0.29%)
COIN : 216.60 (+7.68%)
ASML : 1,565.81 (-1.65%)
ZNM26 : 110-115 (-0.04%)
OXY : 55.14 (+3.98%)
Stocks Supported by Strength in Chip Makers and US Economic News

The S&P 500 Index ($SPX ) (SPY ) today is up +0.49%, the Dow Jones Industrials Index ($DOWI ) (DIA ) is up +0.75%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) is up +1.07%. March E-mini S&P futures (ESH26...

BLK : 1,081.32 (-0.32%)
MSTR : 195.94 (+4.45%)
AMAT : 443.62 (+1.88%)
MPC : 252.48 (+3.11%)
SNDK : 1,547.56 (-0.95%)
ADI : 422.73 (+1.49%)
MLTX : 18.84 (+10.43%)
$IUXX : 29,320.66 (+0.29%)
ASML : 1,565.81 (-1.65%)
ZNM26 : 110-115 (-0.04%)
OXY : 55.14 (+3.98%)
ESM26 : 7,433.50 (-0.04%)
Stock Indexes Rally on Chip Demand Optimism

The S&P 500 Index ($SPX ) (SPY ) today is up +0.55%, the Dow Jones Industrials Index ($DOWI ) (DIA ) is up +0.20%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) is up +1.00%. March E-mini S&P futures (ESH26...

BLK : 1,081.32 (-0.32%)
MSTR : 195.94 (+4.45%)
AMAT : 443.62 (+1.88%)
MPC : 252.48 (+3.11%)
AVGO : 428.43 (-0.37%)
SNDK : 1,547.56 (-0.95%)
MLTX : 18.84 (+10.43%)
$IUXX : 29,320.66 (+0.29%)
ZNM26 : 110-115 (-0.04%)
OXY : 55.14 (+3.98%)
ESM26 : 7,433.50 (-0.04%)
FANG : 196.15 (+3.95%)
MLTX DEADLINE ALERT: Hagens Berman Alerts MoonLake (MLTX) Investors to Today's Lead Plaintiff Deadline in Securities Class Action

SAN FRANCISCO , Dec. 15, 2025 /PRNewswire/ -- Global plaintiffs' rights firm Hagens Berman reminds investors that the Lead Plaintiff Deadline in the securities class action lawsuit against ...

MLTX : 18.84 (+10.43%)
MoonLake Immunotherapeutics Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights – MLTX

The DJS Law Group reminds investors of a class action lawsuit against MoonLake Immunotherapeutics (“MoonLake” or “the Company”) (NASDAQ: MLTX ) for violations of §§10(b)...

MLTX : 18.84 (+10.43%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 24% Buy with a Weakening short term outlook on maintaining the current direction.

Relative Strength just crossed above 50%. The market is indicating support for a bullish trend.

See More Share

Business Summary

MoonLake Immunotherapeutics AG is a clinical-stage biotechnology company. It focused on creating next-level therapies for inflammatory skin and joint diseases. MoonLake Immunotherapeutics AG, formerly known as Helix Acquisition Corp., is based in BOSTON.

See More

Key Turning Points

3rd Resistance Point 23.77
2nd Resistance Point 22.39
1st Resistance Point 20.61
Last Price 18.84
1st Support Level 17.45
2nd Support Level 16.07
3rd Support Level 14.29

See More

52-Week High 62.75
Fibonacci 61.8% 41.05
Fibonacci 50% 34.35
Fibonacci 38.2% 27.65
Last Price 18.84
52-Week Low 5.95

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.